KMT2A and leukemia: As there are reports indicating that incomplete eradication of this aberration in patients with FLT3-ITD+ leukemia may lead to relapse,30,31 the moderate FLT3-ITD inhibition by revumenib raises the question if concomitant inhibition of the Menin–MLL interaction and FLT3-ITD signaling resulted in an even stronger reduction of leukemic propagation.